Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® ...

Stellenbosch University (SU) has announced the opening of the LaunchLab Centre for Epidemic Response and Innovation (Ceri) ...

Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Rokeby brings a distinctive perspective to this exploration through his work as director of the University of Toronto’s BMO ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Finance Income, net was $1.0 million for the three months ended March 31, 2025, compared to $0.7 million in the same period of 2024, representing an increase of $0.3 million, primarily attributable to ...

Ministry of Science & Technology observed Swachhata Pakhwada 2025 from 1st May to 15th May 2025 at its Headquarters in New Delhi and across all its Autonomous Institutions (AIs) and Public Sector Unde ...

Leveraging Northway Biotech's 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for hormone-driven ovarian cancer WALTHAM, MASSACHUSETTS / ACCESS Newswire / May 21, ...

Frontage Laboratories, Inc. officially unveiled its newest Contract Research, Development and Manufacturing Organization (CRDMO) facility during a grand open house event held on May 22, 2025, at its ...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.